Korro Bio Inc. Ordinary Shares KRRO 深 沪
已收盘 09-19 16:00:00 美东时间
38.50
+1.770
+4.82%
华盛通- 最 高40.0708
- 今 开38.26
- 成交量 18.68万股
- 最 低 37.80
- 昨 收 36.73
- 总市值 3.08亿
- 52周最高 97.91
- 市盈率 静 --
- 换手率 2.33%
- 52周最低 9.15
- 委 比 -87.32%
- 总股本 801.14万
- 历史最高 2918.50
- 量 比 3.14
- 振 幅 6.18%
- 历史最低 9.15
- 每 手 1
- 风险率 16.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gold Edges Lower; US Homebuilder Sentiment Rises For September
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Com...
09-18 02:31
Crude Oil Gains Over 1%; US Business Inventories Increase In July
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
09-18 00:16
Korro Bio Board Changes and Strategic Advisor Agreement
An announcement from Korro Bio (KRRO) is now available. David L. Lucchino resig...
08-29 04:29
Here's Why We're Watching Korro Bio's (NASDAQ:KRRO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable busine...
08-16 20:10
Korro Bio’s Chief Scientific Officer Announces Resignation
An update from Korro Bio (KRRO) is now available. Steve Colletti, Ph.D., has an...
06-22 05:14
加拿大蒙特利尔银行：维持Korro Bio(KRRO.US)评级，由优于大市调整至优于大市评级, 目标价120.00美元。
加拿大蒙特利尔银行：维持Korro Bio(KRRO.US)评级，由优于大市调整至优于大市评级, 目标价120.00美元。
05-15 21:03
Korro Bio Q1 2024 Adj EPS $(2.44) Beats $(2.51) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.51) by 2.79 percent.
05-15 04:20
Korro secures $70M financing via private placement
Biopharmaceutical company Korro Bio (NASDAQ:KRRO) entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of ~1.25M shares in a private ...
04-18 20:50
Korro Bio launches $70M PIPE offering
Korro Bio (NASDAQ:KRRO) said Thursday it would raise $70 million through a private placement offering. The company has entered into a subscription agreement with certain new and existing accredited in...
04-18 20:48
Korro Announces $70M Private Placement
Financing led by Deep Track Capital with participation from other leading healthcare investorsPro-forma cash and cash equivalents of approximately $236 million before fees and expensesOn track for regulatory filing for
04-18 20:32
